Hybrid particle immunogens

ABSTRACT

Novel immunogenic compositions are provided involving viral particles composed at least in part of hybrid proteins of at least a portion of a particle forming protein and one or more polypeptides having at least one epitope of interest. Nucleic acid sequences are employed coding for the hybrid protein which are introduced into a host cell for expression, either by themselves or in combination with other DNA sequences coding for particle forming proteins. Expression of the DNA sequences results in formation of particles which may be isolated and used as immunogens for production of antibodies for diagnostics purposes, passive immunization, vaccination, or other uses. 
     Saccharomyces carlsbergensis, 2150-2-3 (pDC103), was deposited on Sep. 7, 1984, at the ATCC and given ATCC Accession No. 20726. Also, Saccharomyces cerevisiae PO17 (pC1/1-MCS29) was deposited at the ATCC on Sep. 5, 1985, and given ATCC Accession No. 20770.

This application is a continuation of application Ser. No. 08/126,115filed 23 Sep. 1993, now abandoned, which is a continuation ofapplication Ser. No. 07/966,291 filed 26 Oct. 1992, now abandoned, whichis a continuation of application Ser. No. 07/128,639 filed 4 Dec. 1987,now abandoned, which is a divisional of application Ser. No. 06/777,976filed 19 Sep. 1985, now U.S. Pat. No. 4,722,840, which is acontinuation-in-part of application Ser. No. 06/650,323 filed 12 Sep.1984, now abandoned.

BACKGROUND OF THE INVENTION FIELD OF THE INVENTION

The immune system is an incredibly sophisticated organization of cells,secreted factors and responses for protecting vertebrates againstdisease caused by pathogens or toxins. The fact that mammals are subjectto disease, but survive in most instances, demonstrates both thefallibility of the system and its extraordinary capabilities. The immunesystem has found wide application for both in vivo and in vitropurposes, where vaccination, passive immunization, and production ofantibodies for in vitro diagnostics, histology, cytology, and the likefind application. With the advent of monoclonal antibodies, the immunesystem has seen an extraordinary expansion of its utilization for theproduction of monoclonal antibodies for a wide variety of purposes,where polyclonal antibodies were inadequate.

The immune system is complex and is not fully understood. The manner inwhich the immune system recognizes foreign immunogens from host peptidesand saccharides has still not been elucidated, but is the subject ofextensive investigation. Numerous instances exist where a mammalian hostis subjected to foreign proteins, where only a weak or undetectableimmune response is obtained. Many vaccines are based on the use ofattenuated organisms, which carry with them the possibility of avirulent organism, which can result in infection upon immunization. Inmany instances, it is desirable to immunize with a surface protein orimmunogenic portion thereof, but this is frequently found to beunsatisfactory due to a weak response or failure to produce antibodiesto the relevant epitopic site. Many proteins or epitopic sites are foundto be weakly immunogenic, so that when injected into a xenogeneic host,little if any neutralizing antibodies are obtained to the site(s) ofinterest.

It is therefore of great interest to be able to prepare compositionswhich demonstrate high immunogenicity to an epitopic site of interest.In this manner, one can obtain an enhanced immune response uponvaccination, provide antibodies which will be active in passiveimmunization and produce antibodies to what are otherwise weaklyimmunogenic epitopic sites in conventional hosts employed for theproduction of antibodies. Further, it would be preferable to producecompositions containing epitopic sites from more than one infectiousagent. These compositions could then be utilized as polyvalent vaccines,allowing for less expensive, more efficient, and safer immunizationregimens.

DESCRIPTION OF THE RELEVANT LITERATURE

The entire genome of Hepatitis B virus has been cloned in E. coli andits nucleotide sequence has been determined (Valenzuela et al., Nature(1979) 280:815-819; Valenzuela et al., Animal Virus Genetics (1980) pp.57-70). Hepatitis B surface antigen particles have been synthesized andassembled in,the yeast S. cerevisiae (Valenzuela et al., Nature (1982)298:347-350). The synthesis and assembly in yeast of Hepatitis B surfaceantigen particles containing the pre-surface antigen region has beendescribed in copending application Ser. No. 621,756, filed on Jun. 18,1984, entitled "Hepatitis Surface Antigen Particle Vaccine." The cloningof the Herpes Simplex virus glycoprotein D gene in E. coli and the genenucleotide sequence has been reported (Watson et al., Science (1982)218:381-384). The cloned glycoprotein D gene has been expressed in yeastas reported in copending application Ser. No. 631,669, filed Jul. 17,1984, entitled, "Improved Expression of Glycoprotein D of Herpes SimplexVirus."

The sequence of the circumsporozoite (CS) protein for the human malarialparasite Plasmodium falciparum has been cloned (Dame et El., Science(1984) 225:593 and Enea et al. ibid. p. 628). CS proteins from P.Falciparum and P. Knowers have been expressed in Escherichia coli (Younget al., Science (1985) 228:958) and yeast (Shard and Godson, Science(1985) 228:879). Also, synthetic peptides from the CS protein of P.Falciparum were found to be immunogenic for mice and rats (Ballot etal., Science (1985) 228:996). All of the above relevant disclosures areincorporated herein by reference.

SUMMARY OF THE INVENTION

Novel immunogenic compositions are provided comprising viral particleswhich include hybrid viral particle forming proteins of a least aportion of a naturally occurring viral particle forming protein and oneor more oligopeptides having one or more epitopic sites of interest. Theoligopeptides can include antigenic regions from bacteria parasites,different viruses, or other infectious agents. The particles are formedby preparing a nucleic acid sequence coding for the hybrid protein,which is introduced into a host cell for expression, either as the soleparticle forming protein or in combination with a nucleic acid sequenceencoding one or more different particle forming proteins. The nucleicacid sequence is expressed in the host to produce polypeptides whichassemble into particles. The particles can be used as immunogens for theproduction of antibodies to both the particle forming polypeptide andthe epitopic sites of interest. The particles may find use as vaccines,or for the production of insatiable, polyclonal or monoclonalantibodies, which antibodies can be used for passive immunization, invitro diagnostics, cytology, histology, or other applications.

DESCRIPTION OF THE SPECIFIC EMBODIMENTS

Novel immunogenic compositions are provided for enhanced immunogenicityof one or more predetermined epitopic sites, by employing apolynucleotide fragment coding for one or more polypeptides oroligopeptides having epitopic sites joined in proper reading frame, withor without the presence of an introit, to a nucleic acid sequence codingfor at least a portion of a particle forming polypeptide, where theresulting hybrid protein retains the capability of particle formation.Particularly, nucleic acid sequences are employed coding for at least aportion of a viral particle forming polypeptide joined at the 5'terminal region in the direction of transcription of the sense strand tothe 3' end in the same orientation of a polynucleotide sequence codingfor one or more epitopic site if interest. The polynucleotide sequencecoding for the epitopic sites of interest is not naturally found joinedto the sequence coding for the particle forming polypeptide. Theresulting hybrid gene which codes for the hybrid protein is joined totranscriptional regulatory and translational initiation and terminationsignals and introduced into a host under conditions for expression andparticle assembly. The assembly may be as a result of the particleformation of solely the hybrid protein or the hybrid protein inconjunction with other particle forming proteins

As part of the process of packaging, viral genes encoding for capsidproteins are expressed in the host and assemble to firm the capsid. Thecapsid may then be isolated in accordance with conventional ways andused as an immunogen for stimulating the formation of antibodies. Therequirements for a particle forming polypeptide to be used in thepreparation of a hybrid particle forming protein are that thepolypeptide is sufficiently stable in the host cell to result in theformation of capsids; that the polypeptide will automatically assembleinto a capsid in the cytoplasm; that the terminus of the particleforming protein or fragment thereof may be modified with one or moredifferent polypeptides (e.g., oligopeptides), whereby the foreignpolypeptides are presented at the surface of the particle in a desiredantigenic confirmation; and the particle forming protein is notcytologic in the expression host.

As exemplary of a particle forming protein which can be prepared in aunicellular microorganism host is the Hepatitis B surface antigen(HBsAg), particularly the precursor to the Hepatitis B surface antigen,preS-Hepatitis B surface antigen (preS-HBsAg).

The particle forming protein of the Hepatitis B virus (HBV) may be usedin its entirety, may be used as a particle forming fragment thereof,usually having at least about 90% of the amino acid sequence,particularly retaining the N-terminus and desirably including at least aportion of the preS, usually at least about 5%, preferably at leastabout 25%, where the amino acids may be removed from any portion of thepreS portion, usually at the N-terminus. The preS polypeptide has 168amino acids, and when a fragment is employed it will usually have about10 to 100 amino acids. The pres portion may involve from about 25 to 75amino acids, usually from about 35 to 65 amino acids of the naturallyoccurring pres portion, particularly the C-terminal portion.

The gene for the particle forming protein may be available or may beobtained in accordance with conventional techniques. The genes encodingfor HBsAg have been described in Valenzuela et al., 1982, supra, whilethe precursor preS-HBsAg gene is described in U.S. application Ser. No.621,756, filed on Jun. 18, 1984, whose relevant disclosure isincorporated herein by reference.

Where the gene coding for the particle forming protein is not available,the protein may be isolated, partially sequenced, and based on the aminoacid sequence, DNA probes can be prepared. The virus may then beisolated, as appropriate, fragmented to provide for fragments of fromabout 5 to 20 kb, and the fragments separated according to molecularweight and screened with the probes for duplex formation. The fragmentsforming duplexes are then cloned, purified, and may be subcloned toprovide for smaller fragments, which are cloned. The subcloned fragmentsare then separated according to molecular weight and screened again withprobes for duplex formation. Those fragments which duplex, may now beused in turn as probes for screening the viral genome, which has beencleaved with mung bean nuclease. This enzyme is found to cleave at aboutthe termini of genes. See McCutchan et al., Science (1984) 225:625-628.

Alternatively, the cloned fragments may be sequenced, open reading framesequences determined and those sequences conforming to known amino acidsequences of the particle forming protein isolated and used to definethe structural gene. As appropriate, the various genes may bemanipulated to remove portions of the structural gene, to modifyspecific nucleotides, which may result in a change in or retention ofthe natural amino acid, which may provide for introduction of arestriction site or other manipulative convenience, or the like.

Superfluous DNA can be removed by restriction, exonuclease digestion,e.g., Bal31, primer repair, in vitro mutagenesis, or other manipulativetechnique. After each manipulation of the fragments to be used forforming the hybrid sequence, the fragments will be cloned, purified andsubjected to the next succeeding manipulation. Depending upon theparticular particle forming polypeptide, the hybrid protein may have theepitope of interest at the N-terminal region or C-terminal region. Thus,the DNA sequence coding for the epitope of interest may have the sensestrand joined in reading frame either at the 3' or 5' end to the 5' or3' end respectively of the sense strand of the fragment coding for theparticle forming protein.

The sequence coding for the oligopeptides of interest may come from anysource, naturally occurring, synthetic or combination thereof, but willnot naturally be joined to the particle forming protein. The naturallyoccurring sequence may be shortened, or otherwise modified to introducerestriction sites, provide for expression host preferred codons, or thelike. Generally, the sequence will be one that does not disrupt thecapability of the particle forming polypeptide. Typically, the sequencewill code for less than about 50 amino acids, often between 10 and 20amino acids, but may be 5 amino acids or less.

Of particular interest are sequences coding for at least one epitopicsite of an oligopeptide, which epitopic site is present on a toxin, orpart of a pathogen, such as a surface or membrane protein, secretedprotein, envelope protein or capsid protein. Thus, the use of theparticles as vaccines would typically involve polypeptides oroligopeptides of interest associated with infectious agents. Suchinfectious agents would include, by way of example and not oflimitation, bacteria both gram-negative and gram-positive; viruses, suchas the herpes viruses, the AIDS-associated retrovirus, and the like;parasites, such as the human malarial parasite Plasmodium falciparum;etc. When the infectious agent has dominant epitopes or those composedof repeating units, the sequences thereof are preferred for inclusion inthe constructs of the present invention. The sequence employed can bemanipulated at its terminal by restriction, ligation of adapters orlinkers, in vitro mutagenesis, primer repair, or the like, to providefor joining to the sequence coding for the particle forming protein.

Various techniques exist for joining DNA fragments. Frequently, therewill be restriction sites proximal to the sites of the intended junctureof the two fragments. In this situation, where the two ends are cohesiveand complementary, and the lost codons are not necessary, the two endscan be joined together, where the proper reading frame is established.Alternatively, adapters may be employed, where the adapters restore someor all of the lost nucleotides, providing for the two fragments to be inproper reading frame or providing different nucleotides, which code foramino acids different from the naturally occurring amino acids at thejuncture. Conveniently, one of the fragments is cloned on a vector,restricted at the appropriate site and then further manipulated, e.g.,by restriction, insertion of an adapter, etc., followed by insertion ofthe other fragment, followed by cloning of the hybrid sequence.

Once the hybrid sequence has been prepared, it may then be furthermodified for expression. This will require that the hybrid sequence bejoined to transcriptional regulatory and translational signals in properorientation for expression in the expression host. Either eukaryotes orprokaryotes may be employed as the expression host, either unicellularmicroorganisms or mammalian cells. In each instance, there are ampleexpression vectors available for expression of the hybrid particleforming protein. For prokaryotes, E. coli, B. subtilis, B. thermophilus,or the like may be employed. For unicellular eukaryotes, S. cerevisiae,S. kluveromyces, S. pombe, or the like, may be employed. Highermammalian cells include mouse cells, human cells, monkey cells, or thelike.

Of particular interest is the expression of the hybrid protein in yeastcells. For expression in yeast cells, various expression vectors may beemployed, usually employing the 2μ replication system, when other thanintegration of the structural gene is desired. Where integration isdesired, the vector may employ an ars for high efficiency oftransformation with integration. The vectors will normally have one ormore markers for selection in yeast, where the marker may provideprototrophy to an auxotrophic host, resistance to a biocide, e.g., toantibiotics such as G418, tunicamycin or heavy metal, such as copper orzinc, or other selective technique.

The yeast transcriptional regulatory initiation sequences can be derivedfrom a variety of genes, particularly the glycolytic genes, such asalcohol dehydrogenase, glyceraldehyde-3-phosphate dehydrogenase,glucose-6-phosphate dehydrogenase, triosephosphate isomerase,phosphofructokinase, etc., or other genes such as acid phosphatase,beta-actin, alpha-amylase, heat shock proteins, metallothioneins, etc.Any convenient transcriptional termination sequence may be employedwhich is operative with the transcriptional initiation sequence,conveniently a termination sequence associated with the same gene as theinitiation sequence. In addition, where integration is involved, thehybrid gene may be placed in tandem with another gene which allows foramplification, such as a metallothionein gene, e.g., copper chelatingene, dihydrofolate reductase gene, etc.

In addition to the other sequences, a prokaryotic replication system mayalso be included, so as to allow cloning at each stage. Variousprokaryotic replication systems exist, ColE1, P-1 incompatibilityplasmids, R6, such as lambda, etc.

The constructs of the subject invention can be diagrammaticallyillustrated by the following formula.

     Tp.sub.i.sup.1 -Tl.sub.i.sup.1 -G-Tl.sub.t.sup.1 -Tp.sub.t.sup.1 !.sub.m -E.sub.n - Tp.sub.i.sup.2 -Tl.sub.i.sup.2 -Im-Tlt.sup.2 -Tpt.sup.2 !f-(Rpe)a-(Rpp)c-(M)d-

wherein:

Tp_(i) intends a regulatory signal for transcriptional initiation;

Tl_(i) intends the regulatory signal for translational initiation;

Tl_(t) intends the regulatory sequence for translational termination;

Tp_(t) intends the regulatory sequence for transcriptional termination;

wherein the superscripts 1 and 2 indicate that the various regulatorysequences may be the same or different, wherein all of the regulatorysequences will be recognized by the same host and be capable offunctioning for expression in the same host;

G is a gene having a DNA sequence coding for a product which protectsthe expression host from stress, such as an antibiotic or heavy metaland results in amplification of the gene and flanking regions, so as toprovide for tandem copies of the gene and flanking regions; desirably,the gene and flanking regions which make up the construct will includesequences having homology with the genome of the expression host, so asto enhance the probability of integration into the genome; particulargenes of interest include the gene encoding dihydrofolate reductase, thegene coding for kanamycin resistance (G418), the gene coding fortunicamycin resistance and a gene coding for a metallothionein, toprovide resistance to heavy metal;

E is an enhancer which enhances the rate of transcription;

Im is the immunogen which has the formula (Ag_(i))_(k) -(prePP )_(b)-Ag_(p) wherein:

Ag_(i) intends the antigen of interest which provides an epitopic sitenot naturally joined to Ag_(p) capable of inducing an immune responsefor formation of an antibody specific for the epitopic site;

prePP intends a polypeptide which will normally be all or a portion of anaturally occurring N-terminal polypeptide, generally cleaved from alarger polypeptide, usually involving Ag_(p) and may serve as a linkbetween Ag_(i) and Ag_(p) ;

m, n and b are 0 or 1;

k and f are each 1 or more, typically 2 or 3; and typically, if k ismore than 1, then f will be 1, and vice versa.

Ag_(p) is a particle forming antigen which will be substantially thesame as a naturally occurring particle forming antigen or portionthereof, which portion is capable of forming a particle in conjunctionwith Ag_(i) and may be derived from any virus which forms a particle ina host and provides for exposure of Ag_(i) for production of antibodies,particularly the HBsAg antigen;

RP_(e) and Rp_(p) are replication systems for eukaryotic and prokaryoticcells;

a and c are 0 or 1;

M is a marker providing for a selection in a cloning or expression host,where the markers may be the same or different and include resistance tobiocides, such as antibiotics, heavy metals, or the like; providingprototrophy to an auxotrophic host; or the like;

d is from 0 to 5, usually 1 to 4;

the sequences in brackets give an indication of the preferred order ofappearance of the DNA sequences, while those portions outside thebrackets may be in any order.

The various sequences may be joined in accordance with conventionaltechniques. Where restriction sites are available outside of functionalsequences such as regulatory sequences, coding sequences, or the like,the two sequences may be joined, where the restriction sites arecomplementary or linkers may be employed for joining the two sequences.Usually, the construct will be built up incrementally, usually employingcloning vectors, where fragments are inserted into the cloning vectorstepwise, cloned and the vectors isolated and purified. Whererestriction sites are not available outside of functional sequences orinconveniently situated in relation to functional sequences, adapterscan be used, which recreate all or a portion of the functional sequenceand join together two functional sequences in proper orientation.Alternatively, convenient restriction sites can be created bymutagenesis of the sequences and such sites can be used in the joiningprocedure. Various techniques for improving the efficiency with whichsequences are joined together include alkaline phosphatase treatment ofone sequence, filling in of sequences to provide for blunt end ligation,tailing, or the like.

Once the construct has been prepared having the necessary functionalsequences, the expression construct may be introduced into a compatiblehost by any convenient technique, such as transformation, e.g.,polyethylene glycol precipitation, conjugation, transfection,transduction, or the like. The recipient cells may then be grown in anappropriate nutrient medium to a desired density, the cells harvested, alysate prepared by any convenient means, e.g., agitation with glassbeads, and the desired protein harvested.

The protein of the subject invention will naturally aggregate to formparticles in the expression host. The particles may be enveloped havinga lipid membrane coat, which may or may not include membrane proteinsencoded for by the virus. Alternatively, the particles may not includethe lipid membrane or the membrane may be present initially or may beremoved, in whole or in part.

The particles may be used as immunogens in a wide variety of ways. Theparticles may be isolated by affinity chromatography employing a columnwhich recognizes either or both of the antigens present, oralternatively, separations can be employed using (density gradients, gelfiltrations and the like. The techniques may be used individually or incombination.

Any of the conventional methods for administration of a dead virusvaccine are applicable. These include applications on a solidphysiologically acceptable base or in a physiologically acceptabledispersion, parenterally, by injection, or the like. The dosage of thevaccine will depend on the route of administration and will varyaccording to the size of the host. Because the vaccine will have few, ifany, side effects, relatively large doses may be used without injury tothe host. Normally, the amount of the vaccine will be from about 1 μg to20 mg per kilogram of host, more usually from about 5 μg to 20 μg givensubcutaneously or intramuscularly, after mixing with an appropriatecarrier or an adjuvant to enhance immunization with the vaccine.

Various methods of achieving adjuvant effect for the vaccine include useof agents such as aluminum hydroxide or phosphate (alum), commonly usedas a 0.05 to 0.1% solution in phosphate buffered saline, admixture withsynthetic polymers of sugars (Carbopol), used as a 0.25% solutionmixture with bacterial cells such as C. parvum or endotoxins orlipopolysaccharide components of Gram-negative bacteria, emulsion inphysiologically acceptable oil vehicles, such as mannide mono-oleate(Aracel A) or emulsion with a 20% solution of a perfluorocarbon(Fluosol-DA) used as a blood substitute.

The amount of the adjuvant which is employed will vary widely dependingupon the nature of the adjuvant, generally ranging from 0.1 to 100 timesthe weight of the immunogen, more usually from about 1 to 10 times.

In many instances it will be desirable to have multiple administrationsof the vaccine, usually not exceeding six vaccinations, more usually notexceeding four vaccinations, and preferably one or more, usually aboutthree vaccinations. The vaccinations will normally be at from 2 to 12week intervals, more usually from 3 to 5 week intervals, with optionalperiodic boosters at intervals of 1 to 5 years. The course of theimmunization may be followed by assays for antibodies to the antigen ofinterest.

The subject particles can also be used in assays for detecting thepresence of antibodies to the antigen of interest. In use in assays, theindividual protein or particle will normally be labeled with one of avariety of labels which find use in assays. These labels have beenextensively reported in the patent and technical literature and includeradionuclides, fluorescers, chemiluminescers, enzymes, enzymesubstrates, small molecules, and the like.

The particle of the subject invention may be used for the production ofantibodies in various mammalian hosts, e.g., murine, bovine, ovine,lagomorpha, human, etc. The antibodies can then be used in immunoassaysfor the detection of the presence of the antigen of interest.Alternatively, the antibodies can be used for passive immunization andmay be administered in vivo in conventional ways to a mammalian host.

The subject particles can be used in conventional ways to produceantisera or monoclonal antibodies (Kohler and Milstein, Nature (1975)256:495-497, which is incorporated herein by reference). For monoclonalantibodies, the hybridomas may be grown in culture or injectedintraperitoneally for formation of ascites fluid or into the bloodstream of an allogeneic host or immunocompromised host. The antibodiesmay then be isolated in conventional ways.

The following examples are offered by way of illustration and not by wayof limitation.

    ______________________________________                                        EXPERIMENTAL                                                                  ______________________________________                                        TE          10 mM Tris-HCl, pH 8.0, 1 mM EDTA                                 EDTA        Ethylene-diamino-tetracetic-acid                                  PBS         Phosphate buffered saline                                         SDS         Sodium dodecyl sulfate                                            BSA         Bovine serum albumin                                              ADH         Alcohol dehydrogenase                                             GAPDH       Glyceraldehyde 3-phosphate dehydrogenase                          HSV         Herpes simplex virus                                              gD          Glycoprotein D                                                    HBV         Hepatitis B virus                                                 HBsAg       Hepatitis B surface antigen                                       pre-S       Pre-surface                                                       HRP         Horseradish peroxidase                                            kbp         kilobase pairs                                                    ______________________________________                                    

All DNA manipulations were done according to standard procedures. SeeMolecular Cloning, T. Maniatis et al., Cold Spring Harbor Lab., N.Y.,1982. Enzymes used in cloning were obtained either from New EnglandBiolabs or Bethesda Research Laboratories and employed according to thesupplier's directions. Yeast were transformed and grown using a varietyof media including selective medium (yeast nitrogen base withoutleucine); YEPD medium, containing 1% (w/v) yeast extract, 2% (w/v)peptone and 2% (w/v) glucose, and others as appropriate and/or detailedbelow. In the case of plating, medium contained 2% (w/v) agar and fortransformation, 3% top agar. Medium compositions have been described bySherman et al., 1979, Methods in yeast genetics: A Laboratory Manual,Cold Spring Harbor Lab., N.Y.

1. Description of vectors used in the construction of the yeastexpression vector for the hybrid antigen (preS-HBsAg-gD andpreS-HBsAg-CS)

1a. Plasmid pC1/1.

See EPO 83/306507.1, which relevant part is incorporated herein byreference.

1b. Plasmid pYHS119.

This vector contains a partial gD gene in a glyceraldehyde-3-phosphatedehydrogenase (GAPDH) expression cassette cloned into the BamHI site ofpC1/1 (described above). The cloned partial gD gene contains twodeletions of 600 bp and 2400 bp in the 5' and 3' end coding regions,respectively. These deletions comprise most of the signal sequence (5')and all of the anchor sequence (3') coding regions. To construct pYHS119two fragments were obtained:

(i) An NcoI-SalI digested vector (6.8 kbp) comprising pBR322 sequences,the GAPDH promoter plus the first seven codons of the GAPDH structuralgene and the GAPDH terminator. This vector was prepared by NcoIdigestion of pUH28 (described below), followed by a partial digestionwith SalI and purification by gel electrophoresis.

(ii) An NcoI-(NarI)SalI fragment (873 bp) containing a partial gD gene.This fragment was obtained as follows: plasmid pYHS115 (described below)was digested with NcoI and SalI, the resulting 1430 bp fragmentcontaining the gD gene was purified by gel electrophoresis andsubsequently digested with NarI. The 873 bp NcoI-NarI fragment wasisolated by gel electrophoresis. A synthetic adapter of the followingsequence: ##STR1## which provides complementary nucleotides to the NarI5' overhang, 3 codons in reading frame, a stop codon and a 5' overhangof SalI, was ligated to the 873 bp NcoI-NarI fragment and then digestedwith SalI to yield the NcoI-(NarI)SalI fragments.

These two fragments were ligated together to yield a pBR322 derivedvector which contains a partial gD gene fused in reading frame to theseven first codons of the GAPDH gene, flanked by the GAPDH promoter atits 5' end and by the GAPDH terminator at its 3' end. The gD expressioncassette was obtained by digesting this plasmid with BamHI and purifyinga 3.4 kbp fragment by gel electrophoresis. This fragment was ligated toBamHI digested, alkaline phosphatase treated pC1/1 (previouslydescribed), to produce pYHS119.

1c. Construction of plasmid pUH28.

Plasmid pUH28 contains the coding and 3' non-coding regions of theHepatitis B surface antigen (HBsAg) gene fused in incorrect readingframe to the first 7 codons of the GAPDH structural gene. This fusion isflanked at its 5' end by the GAPDH promoter and at its 3' end by part ofthe GAPDH coding region followed by the GAPDH terminator. This plasmidwas constructed so as to have an NcoI site at the 3' end of the first 7codons of the GAPDH structural gene with the following sequence:##STR2## When this NcoI end is ligated to the partial gD fragment (seeconstruction of pYHS119, described above) the correct reading frame forthe gD protein is regenerated. The SalI site used in the preparation offragment (i) (described above) is at the 5' region of the GAPDHterminator. Therefore, a deletion of the HBsAg coding plus non-codingregions and GAPDH coding region was obtained by digesting pUH28 withNcoI and partially with SalI.

The construction of pUH28 involves cloning of a fragment that containsthe HBsAg coding and 607 bp of 3' non-coding region prepared frompHBS5-3 Hae2-1 (described below) into the GAPDH containing vector pGAP₂' (described below). To prepare the fragment, pHBS5-3 Hae2-1 waslinearized by PstI digestion, partially digested with NcoI and aPstI-NcoI fragment of 1.9 kbp containing pBR322 sequences, HBsAg codingand 3' sequences was purified by gel electrophoresis. This fragment wassubsequently digested with EcoRI and a 1.2 kbp NcoI-EcoRI fragmentcontaining the HBsAg coding and 3' non-coding regions was purified bygel electrophoresis. Plasmid pGAP₂ ' was linearized with XbaI andtreated with Bal31 to remove approximately 100 bp. The plasmid wassubsequently digested with NcoI and a vector fragment of about 9 kbp waspurified by gel electrophoresis. The NcoI ends of the vector and the 1.2kbp NcoI-EcoRI fragment encoding HBsAg were ligated. The recessed endwas filled in with Klenow and the resulting blunt end was ligated to theblunt end of the vector obtained by Bal31 digestion to produce pUH28.

pHBS5-3 Hae2-1 is a plasmid that contains the HBsAg coding region and607 bp of the 3' flanking sequence. This plasmid is a derivative ofpHBS5-3 which contains the same insert but only 128 bp of 3'untranslated region instead of 607 bp. Plasmid pHBS5-3 has beenpreviously described in copending application, Ser. No. 609,540, filedMay 11, 1984, (pp. 13-14). pHBS5-3 Hae2-1 was constructed as follows.The HBV genome (3.2 kb) was excised from pHB-3200 (Valenzuela et al.,Nature (1979) 280:815-819) by restriction digestion with EcoRI. The 3.2kbp fragment was purified by gel electrophoresis and was recircularizedby ligation of the EcoRI sticky ends. This closed HBV genome wasdigested with HaeII, which cuts in the 3' non-coding region. Recessedends were filled in with Klenow fragment and HindIII linkers wereligated. The DNA was cut with HindIII and subsequently with XbaI, whichhas a single site in the HBsAg coding region. A 1.2 kbp XbaI-HindIIIfragment containing 586 base pairs of the coding sequence of HBsAg and607 base pairs of the 3' non-coding region was isolated by gelelectrophoresis. This fragment was cloned into pHBS5-3 previously cutwith XbaI and HindIII and treated with alkaline phosphatase, to yieldpHBS5-3 Hae2-1.

pGAP-2 is a pBR322 derived vector which contains a BamHI insert that hasthe GAPDH coding sequence, 5' and 3' flanking regions. There are twoXbaI sites in this plasmid: one in the coding region and one in the 3'flanking sequences. pGAP-2' is a derivative of pGAP-2 in which the XbaIsite present in the 3' flanking region has been eliminated. For thispurpose, 50 μg of pGAP-2 were partially digested with XbaI, treated withBal31 to remove 25 base pairs per end, and ligated. The plasmids wereused to transform E. coli HB101 and the transformants were selected forloss of the XbaI site in the 3' flanking region.

1d. Construction of pYHS115.

Plasmid pYHS115 contains the gD gene in a glyceraldehyde-3-phosphatedehydrogenase (GAPDH) expression cassette cloned into the BamHI site ofpC1/1 (described above).

The GAPDH expression cassette was constructed as follows. Threefragments were prepared (as described in detail below):

(a) A BamHI-HindIII fragment (1407 bp) containing 346 bp of pBR322 and1061 bp of the GAPDH promoter;

(b) A HindIII-SalI fragment (1430 bp) containing the gD gene, and

(c) A SalI-BamHI fragment (900 bp) containing the GAPDH terminator.

These fragments were ligated together and the mixture was digested withBamHI. The 3.7 kbp resulting cassette was isolated by gelelectrophoresis and ligated to BamHI cut, alkaline phosphatase-treatedpC1/1.

Fragment (a) was prepared by completely digesting pGAP347 (describedbelow) with BamHI followed by partial digestion with HindIII. Theresulting 1407 bp fragment containing 346 bp of pBR322 and 1061 bp ofthe GAPDH promoter was isolated by gel electrophoresis.

Plasmid pGAP347 which contains the GAPDH promoter (1061 bp) cloned intopBR322 was constructed (see copending application Ser. No. 468,589,filed Feb. 22, 1983):

PolyA+ RNA was isolated from S. cerevisiae yeast strain A364A.Double-stranded cDNA was synthesized using AMV reverse transcriptase andE. coli DNA polymerase I. Poly-dC-tails were added to thedouble-stranded cDNA molecule using deoxynucleotide terminaltransferase. Poly-dC-tailed cDNA was annealed to poly-dG-tailed pBR322and used to transform E. coli HB101. One thousand transformants werescreened by colony hybridization to labeled PolyA+ RNA, and a subsetfurther examined by restriction endonuclease mapping, and DNAsequencing. Three clones containing GAPDH sequences were isolated fromthe pool. One clone (pcGAP-9) contained an insert of about 1200 basepairs and was used for further work.

A yeast gene library was prepared by inserting fragments obtained afterpartial digestion of total yeast DNA with restriction endonuclease Sau3Ain lambda phage Charon 28, according to Blattner et al., Science (1977)196:161-169. Several fragments containing yeast GAPDH coding sequenceswere isolated by screening the phage library with labeled DNA frompcGAP-9. The yeast GAPDH gene of one of these clones was subcloned inpBR322 as a 2.1 kbp HindIII fragment (pGAP-1). The GAPDH promoter regionwas isolated from these clones. A HhaI-HindIII fragment of about 350 bpcontaining the 3' portion of the promoter was obtained by: (a) digestionof pGAP-1 with HinfI to generate an approximately 500 bp segment whichincludes the 3' part of the promoter and a region encoding theN-terminal amino acids of GAPDH; (b) resection with Bal31 to yield a 400bp fragment lacking the GAPDH coding region (3'-terminus one baseupstream from the ATG initiator codon); (c) addition of HindIII linkers;and (d) cleavage with HhaI to yield a 350 bp HhaI-HindIII fragment. Asecond HindIII-HhaI fragment of about 700 bp containing the 5' portionof the promoter was isolated from pGAP-1, ligated to the 350 bpHhaI-HindIII fragment and treated with HindIII. The resulting 1061 bpHindIII fragment was isolated by gel electrophoresis and cloned inHindIII digested, alkaline phosphatase treated pBR322 to producepGAP347.

Fragment (b) was obtained as follows. Clone H, isolated from the HSV-1Patton library was digested with SacI. A 2.9 kbp SacI fragment waspurified by gel electrophoresis and subsequently digested with HindIIIand NruI. The 1430 bp HindIII-NruI fragment containing the gD gene waspurified by gel electrophoresis, ligated to NruI-SalI adapters of thefollowing sequence: ##STR3## and digested with SalI.

Fragment (c) was obtained as follows. A 900 bp fragment containing theGAPDH terminator was obtained by BamHI and SalI digestion of pUH28(described above) and purification by gel electrophoresis.

1e. Construction of plasmid pDC101.

This vector contains the preS-HBsAg gene (including 55 codons of thepre-S region) in a GAPDH expression cassette cloned into the BamHI siteof a pBR322 derivative (pBRΔR1-Sal, described below). To construct thisplasmid, the 3.2 kbp BamHI expression cassette was excised frompHBpreSGAP347/19T (described below) by BamHI digestion. Afterpurification through gel electrophoresis, the 3.2 kbp BamHI fragment wasligated to BamHI-digested, alkaline phosphatase treated pBRΔR1-Sal andcloned in E. coli to yield pDC101.

1f. Construction of plasmid pBRΔR1-Sal.

This plasmid is a derivative of pBR322 in which the region between theEcoRI site and SalI site has been deleted and a BamHI site has beencreated. This plasmid was constructed by digesting pBR322 with EcoRI andSalI. After filling in the overhanging ends with the Klenow fragment,BamHI linkers were ligated, followed by BamHI digestion and the vectorwas recircularized and cloned to yield pBRΔR1-Sal, which contains noEcoRI site.

1g. Construction of pHBpreSGAP347/19T.

A cassette containing the yeast glyceraldehyde-3-phosphate dehydrogenase(GAPDH) promoter region, the pre-S HBV region comprising 165 bp encoding55 amino acids; the coding sequence for the surface antigen (HBsAg) genein reading frame with pre-surface (pre-S) sequences; and the GAPDHterminator region, was prepared by ligating the following fourfragments: a) a 1407 bp BamHI-HindIII fragment that contains the GAPDHpromoter; b) a 14 bp HindIII-EcoRI adapter molecule coding for the firstthree amino acids of the pre-S region; c) a 250 bp EcoRI-XbaI fragmentencoding a segment of the pre-S region (52 amino acids) and the first 32amino acids of the HBsAg N-terminal region, and d) an approximately 1580bp XbaI-BamHI fragment containing sAg coding region and the GAPDHterminator.

These four fragments were ligated in steps as follows: 4 picomoles offragment a (GAPDH promoter) were ligated to 260 picomoles ofphosphorylated fragment b (14 bp synthetic adapter) in the presence of10 units of T4 DNA ligase. The product (fragment a-b) was separated froman excess of adapter molecules by preparative gel electrophoresis.Approximately 1.5 picomole of isolated fragment a-b was ligated to 1.5picomoles of fragment c, a 250 bp EcoRI-XbaI pre-S and HBsAg N-terminalregion in the presence of 10 units of T4 DNA ligase. Approximately 1picomole of the product (fragment a-b-c) was ligated to 1 picomole offragment d (1580 bp XbaI-BamHI, HBsAg C-terminal region and GAPDHterminator) and to 0.01 picomole of BamHI-digested yeast vector pC1/1 inthe presence of 5 units of T4 DNA ligase. A plasmid containing thecassette cloned in pC1/1 was isolated after transformation of E. coliHB101 This plasmid was named pHBpreSGAP347/19T. The strategy followed toobtain fragments a, b, c and d is described below.

Fragment a) A 1407 bp BamHI-HindIII fragment containing 346 bp of pBR322and a 1061 bp of the GAPDH promoter was prepared by digesting 50 μg ofplasmid pHBS56-GAP347/33 (described below) with BamHI and HindIII (10units each). The fragment was isolated by preparative gelelectrophoresis in 1% agarose.

Plasmid vector pHBS-56GAP347/33, which contains HBsAg under control ofthe GAPDH promoter and the ADH terminator was constructed as follows.Total digestion of pGAP-347 (previously described) with SphI followed bypartial digestion with HindIII yielded an approximately 1700 bpSphI-HindIII fragment having about 1060 bp which included the GAPDHpromoter and about 530 bp of pBR322. The 1700 bp SphI-HindIII GAPDHpromoter fragment was ligated with the 840 bp HindIII-HindIII fragment(containing the HBsAg coding region, 26 bases of 5' non-coding regionand 128 bp of 3' non-coding region, obtained from pHBS-56, describedbelow) and then with the 350 bp HindIII-SphI fragment containing theADH-1 termination region (isolated from pHBS-56). The 2,900 bp SphIexpression cassette was isolated and cloned in pHBS-56 previouslydigested with SphI. The resulting plasmid (pHBS-56GAP347/33) in whichthe promoter, gene and termination regions were in the properorientations was isolated.

Plasmid pHBS56 which contains the HBsAg gene under regulation of the ADHpromoter and terminator, was obtained as follows: A TaI-HpaI fragmentobtained from the HBsAg coding region which included 26 bp of the pre-Sregion, 681 bp of the sAg region and 128 bp of the 3'-untranslatedregion (Valenzuela et al., Nature (1979) 280:815-819), was ligated toEcoRI linkers and cloned at the EcoRI site in pBR322. The EcoRI linkershave the sequence GGAATTCC. The plasmid pHBS5 was thus obtained.

The HBsAg-DNA segment of pHBS5 was excised by EcoRI digestion,blunt-ended with the Klenow fragment and joined at both ends withHindIII linkers of the following sequence CAAGCTTG. After digestion withHindIII, the HBsAg fragment was inserted into the HindIII site of theplasmid pADH5 (described below) which had been digested at the HindIIIsite intermediate the ADH1 promoter and terminator sequence. A plasmidwith the HBsAg gene in the correct orientation as determined byrestriction analysis was designated pHBS22. pHBS22 was digested withSphI to obtain a fragment of about 1500 bp containing the HBsAgexpression cassette and inserted into SphI digested pC1/1 to providepHBS56.

Plasmid pADH5 contains 1500 bp ADH1 promoter fragment terminating atposition -9 (Hitzeman et al., Nature (1981) 293:717) joined with aHindIII site to an approximately 450 bp terminator unit from nucleotides913 to 1368, cloned into the BamHI site of the vector YEp13 (Broach andHicks, Gene (1979) 8:121).

Fragment b) A 14 bp HindIII-EcoRI adapter molecule coding for the firstthree amino acids of the pre-S region (met-glu-trp) and including thefive additional bases for the restriction sites was obtained by chemicalsynthesis ##STR4##

Fragment c) A 250 bp EcoRI-XbaI fragment encoding a segment of the pre-Sregion (52 amino acids) and the first 32 amino acids of the (HBsAg)N-terminal region was obtained by digestion of plasmid pHBV-3200 (50 μg)(Valenzuela et al., Nature (1979) 280:815-819) with the enzymes EcoRIand XbaI (10 units each) and isolated by preparative gel electrophoresisin 6% polyacrylamide.

Fragment d) An approximately 1580 bp XbaI-BamHI fragment containingabout 680 bp coding for the remaining C-terminal region of the HBsAgprotein (194 amino acids) and 3' HBsAg non-coding region andapproximately 900 bp corresponding to the GAPDH terminator region. Thisfragment was obtained by digesting (50 μg) of the plasmid pHBS70-7Δ(described below) with XbaI and BamHI (10 units each) and the resulting1580 bp fragment isolated by preparative gel electrophoresis

Plasmid pHBS70-7Δ is a pC1/1 derivative which contains a GAPDHexpression cassette for the HBsAg gene cloned into a BamHI site. Thiscassette was obtained from plasmid pUH-7Δ, a pBR322 derivative which wasconstructed from pUH7, as follows.

Plasmid pUH7 contains the coding and 3' non-coding region of HBsAg geneflanked at its 5' end by the GAPDH promoter and at its 3' end by part ofthe GAPDH coding region followed by the GAPDH terminator. This plasmidis almost identical to pUH28 (described previously), the only differencebeing that pUH7 does not contain the seven first codons of the GAPDHstructural gene present in pUH28. Plasmid pUH7 was constructed aspUH-28, the only difference residing in the extent of the Bal31resection of PGAP₂ so that in pUH7 all nucleotides corresponding to thefirst codons of the GAPDH structural gene were removed by Bal31.

pUH-7Δ is a plasmid derived from pUH7 in which part of the 3' non-codingregion of the HBsAg. gene and the coding region of GAPDH gene-have beendeleted. For this construction, two fragments were prepared. The firstcontains pBR322 sequences and the. GAPDH promoter and terminatorsequences. This fragment was obtained by digestion of pUH7 with NcoI,followed by a partial digestion with SalI. The NcoI-SalI vector band(approximately 7 kbp) was purified by gel electrophoresis. The secondfragment containing the HBsAg coding region with 128 base pairs of 3'untranslated region was obtained by NcoI-HpaI digestion of pUH7. The 0.8kbp fragment was isolated by gel purification. Both fragments wereligated through their NcoI sticky ends, the recessed ends were filled inwith the Klenow fragment and the resulting blunt ends ligated to yieldpUH-7Δ.

2. Preparation of immune sera and antibodies for immunoassays

2a. Rabbit serum against HSV1 glycoproteins.

HSV1 glycoproteins were prepared by affinity chromatography of HSV1 witha lentil lectin column. The glycoprotein mixture was used to immunizerabbits.

2b. Rabbit antibodies against HSV1 glycoproteins.

The serum against HSV1 glycoproteins (obtained as in a.) was adsorbed toHSV1 glycoproteins bound to a lentil lectin column. The adsorbedmaterial was subsequently eluted to yield purified antibodies againstHSV1 glycoproteins.

2c. Monoclonal antibody against HBsAg (3A11).

HBsAg was produced by genetically engineered yeast as described byValenzuela et al. (Nature (1982) 298:347-350). This antigen was used toprepare mouse monoclonal antibodies following conventional procedures(Kohler and Milstein, Nature (1975) 256:495-497).

2d. Monoclonal antibody against CS peptides (2A-10).

Monoclonal antibodies against synthetic CS peptides were obtained fromDr. V. Nussenzweig, New York University.

3. Immunoassays

3a. Capture of hybrid antigen with anti-HSV1 glycoprotein coated beadand color development with anti-HBsAg antibody coupled to horseradishperoxidase (HRP).

Polystyrene beads coated with antibody against HSV1 glycoproteins wereincubated with different dilutions of yeast extracts (or controls) inmicrotiter wells for 2 hr at 42° C. During incubation, gD antigen shouldbind to the solid phase antibody. After washing the beads to removeunbound material, a second antibody against HBsAg conjugated with HRP(from Abbott Auzyme® kit) was incubated with the antibody antigencomplexes on the beads for 2 hr at room temperature and overnight at 4°C. An antibody-antigen-antibody sandwich should be formed with dependsupon the antigen molecules containing both antigen determinants (gD andHBsAg). Beads were washed to remove unbound conjugates. The peroxidaseactivity (which is proportional to the amount of HBsAg) was assayed by acolorimetric method using o-phenylenediamine (OPD, Abbott) and the colordevelopment was determined by absorbance at 492-600 nm. Within limits,the greater the amount of antigen in the sample, the higher theabsorbance at 492-600 nm. Results are expressed as the total number ofOD₄₉₂₋₆₀₀ units per ml of yeast extract.

3b. Capture of hybrid antigen with anti-HBsAg coated bead and colordevelopment with HRP conjugated goat anti-rabbit antibody bound torabbit anti-HSV1 glycoprotein antibody.

Beads coated with guinea pig antibodies against HBsAg (from the AbbottAuzyme® kit) were incubated with yeast extracts (or controls) for 2 hrat 42° C. After washing with water, a 1/200 dilution of the secondrabbit antibody against HSV1-glycoprotein was added. Incubation wascarried out for 2 hr at room temperature followed by incubationovernight at 4° C. After washing with water, a third peroxidaseconjugated goat anti-rabbit antibody was added, and incubation wascontinued for 1 hr at room temperature. Peroxidase activity wasdetermined as above and color development was measured at 492-600 nm.

3c. HBsAg ELISA assay

Beads coated with guinea pig antibodies against HBsAg (from theAbbott-Auzyme® kit) were incubated with yeast extracts (or controls) for2 hr at 42° C. After washing with water, a second peroxidase conjugated,goat-anti guinea pig antibody was added, and incubation was continuedfor 1 hr at room temperature. Peroxidase activity was determined asabove and color development was measured at 492-600 nm.

4. Western analysis

Transformed yeast cells were electrophoresed on 10% polyacrylamide gels(Laemmli, Nature (1970) 277:680) and proteins were subsequentlyelectroblotted onto nitrocellulose filters (Towbin et al., Proc. NatlAcad. Sci. USA (1979) 76:3450). Two identical filters were blotted. Onefilter was preincubated for one hour with 10% goat serum in PBS andsubsequently treated for 12 hr at 4° C. with rabbit anti-HSV1glycoproteins antiserum or with monoclonal antibody (2A-10) against CSpeptides. The filter was washed with 5% goat serum in PBS and a secondgoat anti-rabbit or anti-mouse antibody conjugated with horseradishperoxidase (Boehringer-Mannheim) was added. Finally the filter wasincubated with horseradish peroxidase color development reagent(Bio-Rad) and washed.

The second filter was washed for 1 hr with 0.5% gelatin in PBS andsubsequently incubated with the monoclonal antibody (3A11) against HBsAgprepared as previously described for 12 hr at room temperature. Thefilter was washed with PBS and a second goat anti-mouse antibodyconjugated with horseradish peroxidase (Boehringer-Mannheim) was added.Finally the filter was incubated with horseradish peroxidase colordevelopment reagent (Bio-Rad) and washed.

RESULTS

1. Construction of pDC103, an expression vector for the hybrid antigen(preS-HBsAg-gD)

The fragment containing the gD gene was cloned into a single EcoRI sitepresent in the pre-S region of plasmid pDC101 (previously described).The EcoRI site spans codons 3 and 4 of this region. The preparation ofthe fragment containing the gD gene, the linearization and phosphatasetreatment of the vector pDC101, the ligation of gD fragment and vector,and the transformation of E. coli HB101 are described below.

1a. Linearization and phosphatase treatment of pDC101.

Ten μg of pDC101 were linearized with EcoRI, which cuts within the thirdand fourth codons of the pre-S region. The linearized plasmid wastreated with 38 units of calf intestine phosphatase (Boehringer) for 45min at 37° C. The reaction was stopped by adding EDTA and SDS to finalconcentrations of 20 mM and 0.5%, respectively, and heating for 10 minat 65° C. The reaction mix was extracted with phenol:chloroform:isoamylalcohol (25:24:1), the aqueous phase was passed through a CL6B column toremove SDS, and concentrated to 60 μl with butanol.

This sample was loaded onto a 1% preparative agarose gel and the 6930 bpband was electroeluted. The electroelution mix was concentrated withbutanol, extracted with phenol:chloroform:isoamyl alcohol (25:24:1) andprecipitated with ethanol. The linearized and phosphatase treated vectorwas resuspended in TE at a concentration of approximately 50 ng/μl.

1b. Preparation of the fragment containing gD gene.

The gD containing fragment was obtained from pYHS119 (previouslydescribed). For this purpose, 10 μg of pYHS119 were digested with 100units each of BamHI and NcoI in a 300 μl reaction. After incubation for3 hr at 37° C., the reaction mixture was loaded onto a preparative 1%agarose gel and the 1788 bp BamHI-NcoI fragment containing the gDfragment and GAPDH terminator was electroeluted from the gel. Afterconcentration with butanol, the electroeluted DNA fragment was extractedwith phenol:chloroform:isoamyl alcohol (25:24:1), precipitated withethanol and resuspended in TE at a concentration of 50 ng/μl.

Approximately 2.5 μg of the 1788 bp fragments were digested with 30units of NarI which cuts at the 3' end of the gD gene producing twobands (888 bp and 900 bp for the fragments containing gD and GAPDHterminator, respectively). The reaction mixture was extracted withphenol:chloroform:isoamyl alcohol (25:24:1) and was precipitated withethanol. The pellet was resuspended in 20 μl of TE.

An EcoRI-NcoI adapter having the following sequence was synthesized:##STR5##

This adapter regenerates the EcoRI and NcoI sites when ligated to pDC101vector and gD fragment, respectively. It also provides for codons 4through 7 of the pre-S region and the first codon of the gD fragment. Asecond adapter, having the following sequence, was synthesized: ##STR6##

This adapter NarI-(EcoRI) regenerates the NarI site but not the EcoRIsite when ligated to pDC101 vector and gD fragment, respectively It alsoprovides for the last three codons of the gD fragment and for the eighthcodon of the pre-S gene.

Both adapters were ligated to the 880 NcoI-NarI fragment containing gD.Ligation was carried out for 17 hr at 14° C. The mixture was thenelectrophoresed in a 1% agarose gel, and the band in the region between873 bp and 1078 bp (according to φx/HaeIII MW standards) waselectroeluted. The DNA solution was concentrated with butanol, extractedwith phenol:chloroform:isoamyl alcohol (25:24:1) and precipitated withethanol. The pellet was resuspended in water (30 μl ).

1c. Ligation and transformation of E. coli HB101.

The purified gD fragment (with ligated adapters) was kinased and ligatedto EcoRI linearized, alkaline phosphatase treated pDC101. Ligation wascarried out for 2.5 hr at room temperature. The reaction mixture wasprecipitated with ethanol, resuspended in water and used to transform E.coli HB101. Plasmid pDC102 was thus obtained.

1d. Construction of pDC103 by cloning of BamHI cassette from pDC102 intopC1/1.

Plasmid pDC102 was partially digested with BamHI. The resulting 4203 bpfragment containing the hybrid antigen under the control of the GAPDHpromoter and terminator, was purified by gel electrophoresis and ligatedto BamHI digested, alkaline phosphatase treated pC1/1 (describedpreviously). Ligation was carried out for 3 hr at room temperature. Thereaction mixture was precipitated with ethanol, resuspended in water andused to transform E. coli HB101. Plasmid pDC103 was thus obtained.

2. Demonstration that Herpes simplex virus gD epitopes and HBsAgepitopes are present in a fusion protein

2a. Immunoassays.

To determine whether HSV gD and HBsAg epitopes were present in the samemolecule, yeast lysates of cells transformed with pDC103 or withpHBpreSGAP347/19T (control plasmid, described previously) were testedusing each of the two immunoassays previously described.

Plasmid pDC103 or pHBpreSGAP347/19T were used to transform Saccharomycescarlsbergensis strain 2150-2-3 (Mat a, ade 1, leu 2-04, cir°) followingthe procedure of Hinnen et al., Proc. Natl. Acad. Sci. USA (1978)75:1929-1933. Transformants were selected on leu-plates.

Single transformant colonies were inoculated into 2.5 ml of selectiveleu-medium and were grown for 24 hr at 30° C. An aliquot of 0.5 ml ofthis saturated culture was inoculated into 50 ml of YEPD containing0.002% adenine and grown to an OD₆₅₀ 6 to 10. Cell free lysates wereprepared by agitation with glass beads in lysis buffer (10 mM NaPO₄, pH7.5, 0.1% Triton X-100) and removal of cell debris by centrifugation.Lysates were diluted in assay buffer (50 mM NaPO₄, pH 7.0, 1% BSA) andseveral dilutions were tested.

Table 1 details the results obtained in the sandwich assay using theimmobilized anti-HSV1 glycoprotein antibody to capture the antigen and asecond soluble anti-HBsAg antibody conjugated with HRP. Colordevelopment is proportional to the HBsAg epitopes present in the antigenbound to the beads coated with anti-HSV1 glycoprotein antibody. As Table1 shows, yeast lysates from transformants harboring pDC103 contained ahybrid antigen capable of forming a complex with both the immobilizedand the soluble antibodies while control lysates from cells carrying thecontrol plasmid which produce HBsAg did not have such capability. Theseresults indicate that both HBsAg and gD epitopes were present in thesame molecules in lysates from pDC103 transformants.

                  TABLE 1                                                         ______________________________________                                        HBsAg epitopes present in antigen bound to immobilized                        anti-HSV1 glycoprotein antibody.                                                         Absorbance                                                                    (492-600 nm units/ml)                                              Lysate                                                                              μl lysate                                                                             control lysate                                               dilution                                                                            in assay   (pHBpreSGAP347/19T)                                                                          pDC103 lysate                                 ______________________________________                                        1:100  2 μl   0.045          0.058                                         1:100  5 μl   0.076          0.071                                         1:100 10 μl   0.071          0.109                                         1:100 20 μl   0.068          0.143                                         1:100 50 μl   0.046          0.244                                         ______________________________________                                    

Similar results are obtained using the immobilized anti-HBsAg antibodyto capture the antigen and a second soluble anti-HSV1 glycoprotein todetect gD epitopes. In this case color development is proportional to gDepitopes present in the antigen bound to the bead coated with anti-HBsAgantibody. These results are shown in Table 2.

                  TABLE 2                                                         ______________________________________                                        Glycoprotein D epitopes present in antigen bound to                           immobilized HBsAg antibody.                                                              Absorbance                                                                    (492-600 nm units/ml)                                              Lysate                                                                              μl lysate                                                                             control lysate                                               dilution                                                                            in assay   (pHBpreSGAP347/19T)                                                                          pDC103 lysate                                 ______________________________________                                        1:500 10 μl   -0.006         0.147                                         1:100 10 μl   0.136          0.458                                         1:100 50 μl   0.170          1.391                                         1:100 100 μl  0.479          >2.0                                          ______________________________________                                    

Results shown in Tables 1 and 2 indicate that both gD and HBsAg epitopeswere present in the same molecule. Furthermore, they indicate that thehybrid antigen synthesized in yeast was present assembled intoparticles, since EBsAg monomers react very poorly with the antibodies inthe Abbott Auzyme® immunoassay, which were employed for binding toHBsAg.

2. Western Analysis

To further containing gD fusion protein, containing gD and HBsAgepitopes was being synthesized, a Western analysis (previouslydescribed) was performed on yeast extracts using sera against gD or amonoclonal antibody against HBsAg.

To this purpose, yeast strain 2150-2-3 was transformed with pDC103,pYHS119, pHBpreSGAP347/19T or pC1/1 (the latter three are controls).Transformants were selected on leu-plates.

Single transformant colonies were inoculated into 2.5 ml of selectiveleu⁻ medium and were grown for 24 hr at 30° C. An aliquot of 0.5 ml ofthis saturated culture was inoculated into 50 ml of YEPD containing0.002% adenine and grown to low density (A₆₅₀ 1.2-2.3). Cells wereharvested, and approximately 150 to 300 μl of packed cells wereresuspended in 100 μl of sample buffer for protein gels (Laemmli, Nature(1970) 227:680). Samples were boiled, vortexed and insoluble materialwas removed by centrifugation.

An aliquot (25 μl ) of each sample was loaded onto each of two 10%polyacrylamide gels (Laemmli, supra). Both gels were electrophoresed atthe same time. After electrophoresis, proteins were blotted ontonitrocellulose filters (BA 85, 0.45 μm, Schleicher and Schuell)following the procedure of Towbin et al. (Proc. Natl. Acad. Sci. U.S.A.(1979) 76:4350).

One filter was treated with rabbit anti-HSV1 glycoprotein antibody andcolor was developed using a second goat anti-rabbit antibody conjugatedwith horseradish peroxidase (as previously described). Using thisprocedure, a strong band of approximately 65 kd was detected in extractsof yeast cells transformed with pDC103. This molecular weight is veryclose to the expected size (64.6 kd) of the preS-HBsAg-gD fusion,calculated from the cloned DNA sequence. Therefore, the resultsindicated that a fusion protein was being synthesized in yeasttransformed with pDC103. As expected, a much smaller band (˜30 kd) whichhas the expected size for gD was detected in extracts of yeast cellstransformed with pYHS119, while no bands reactive with anti-gD weredetected in extracts from pC1/1 or pHBpreSGAP347/19T transformants.

The second identical filter was treated with a monoclonal antibody(3A11) against HBsAg and color was developed using a second goatanti-mouse antibody conjugated with horseradish peroxidase (previouslydescribed). Using this procedure a 65 kd band was detected in extractsof yeast cells transformed with pDC103, while a 30 kd band was detectedin extracts from cells transformed with pHBpreSGAP347/19T and no bandswere present in extracts of pYHS119 or pC1/1 transformants. Theseresults confirmed that a fusion protein which contains both gD and HBsAgepitopes, was being synthesized in yeast cells carrying pDC103. Thisfusion protein had the expected size (65 kd) to account for the gD (30kd) and HBsAg (30 kd) fragments.

3. The gD-HBsAg fusion protein is assembled into particles

To confirm that the preS-HBsAg-gD fusion protein was being assembledinto particles, lysates of strains transformed with pDC103 weresubmitted to density gradients in CsCl. Lysates from cells harboringpHBpreSGAP347/19T were used as control.

Single transformant colonies were inoculated into 2.5 ml of selectiveleu⁻ medium and were grown for 30 hr at 30° C. An aliquot of 2 ml ofthis saturated culture was used to inoculate 200 ml of selective leu⁻medium and cells were grown at 30° C. until an OD₆₅₀ 1 to 3. Cell freelysates were prepared by agitation with glass beads in lysis buffer (10mM NaPO₄, pH 7.5, 0.1% Triton X-100) and removal of cell debris bycentrifugation. An aliquot of 0.6 ml was loaded onto a CsCl gradientprepared by adding 5.3 ml of a solution of 1.4 gm CsCl per ml of 10 mMNaPO₄ , pH 7.5 and overlaying it with 5.3 ml of a solution of 1.4 gmCsCl per ml of the same buffer in a SW-41 polyallomer tube.

Gradients were centrifuged at 30 Krpm for 36 hr at 4° C. Twenty-three0.5 ml fractions were collected and HBsAg activity was detected in eachof them using the Abbott Auzyme® assay. Protein was determined by theBio-Rad assay. Table 3 shows the results obtained.

Lysates from cells harboring the hybrid construction (pDC103) contain asingle peak of HBsAg activity banding in fractions 8 to 12 with maximalactivity in fraction 10, corresponding to about 1.25 gm CsCl/ml. Thisactivity comigrates with that detected in control lysates indicatingthat the preS-HBsAg-gD fusion protein is being assembled into particlessimilar to those obtained with HBsAg alone, which appears to beenveloped.

                  TABLE 3                                                         ______________________________________                                        HBsAg activity in fractions of CsC1 gradient                                         HBsAg Activity* (ng/ml)                                                Fraction             control lysate                                           Number   pDC103 lysate†                                                                     (PHBpreSGAP347/19T)††                      ______________________________________                                         1        0            310                                                     2        4            400                                                     3       12            500                                                     4       10            640                                                     5       10            760                                                     6       22          1,300                                                     7       138         2,300                                                     8       330         5,200                                                     9       2,800       19,800                                                   10       3,800       75,000                                                   11       1,240       44,000                                                   12       430         6,800                                                    13       106         1,700                                                    14       40          1,300                                                    15       38            330                                                    16        4            210                                                    17        4            48                                                     18       16            72                                                     19       12            155                                                    20       30            370                                                    21        8            30                                                     22       28            15                                                     23       150           155                                                    ______________________________________                                         *HBsAg activity determined by the Abbott Auzyme ® assay.                  †HBsAg activity of lysate loaded on gradient; 6.5 μg/ml.            ††HBsAg activity of lysate loaded on gradient; 34 μg/ml.

4. Construction of pC1/1-MCS expression vectors for the hybrid antigen(preS-HBsAg-CS)

4.a. Synthesis of the MCS coding region and cloning into pDC101

The plasmid pC1/1-MCS is a hybrid of a repeat region from Plasmodiumfalciparum circumsporozoite (CS) in conjunction with HBSAg-PreS. Thegenes encoding the CS proteins of P. falciparum have been cloned and thestructures of the polypeptides elucidated (Dame et-al., Science(1984)-225:593 and Enea et al., Science (1984) 225:628, both of whichare incorporated herein by reference). The primary immunodominantepitopes are located within a large domain of the CS molecule formed bytandem repeated sequences.

Oligomers encoding the four amino acide repeat Asn.Ala.Asn.Pro, whichcomprises 37 out of 41 repeat tetrads of the P. falciparum CS, werekinased and ligated to form concatemers of varying lengths. Kinasedlinkers, encoding Asn.Val.Asp.Pro (4/41 tetrads), were ligated to bothends creating EcoRI overhangs and several other restriction sites forscreening orientation. The sequence of both the repeat tebrads andendlinkers is shown below. ##STR7##

This ligation mixture was digested with EcoRI and run on a 5% nativeacrylamide gel. A band spanning 300-600 base pairs was cut out, elutedand ligated into pDC101 (described previously) which had been linearizedwith EcoRI and phosphatased as described in Section 1a. Seven insertsranging in size from 1-10 repeats were isolated (see Table 4).

In order to isolate the BamHI expression cassette containing the CSrepeats for cloning into pC1/1 (previously described), the repeats wereinitially cloned into pHG101. This vector is identical to pDC101, butlacks a BamHI site in the preS coding region.

For the construction of pHG101 the following procedure was followed:pDC101 was completely digested with EcoRI, then partially digested withBamHI. The largest fragment resulting from the digestion was purified bycutting the corresponding band out of a 1% agarose gel and eluting theDNA. This fragment was subsequently phosphated. The procedure removed 30base pairs of preS coding region between the EcoRI site and the BamHIsite. The deleted sequence was replaced by ligating, to the fragment,kinased 30-mers that code for the same amino acids present in pDC101,but which do not regenerate the BamHI site (sequence is shown below).##STR8##

EcoRI fragments from four PDC101 clones (indicated in Table 4) weresubcloned into pHG101. For this purpose, the pDC101-MCS plasmids weredigested with EcoRI. The inserts were purified by gel electrophoresisand ligated to pHG101, which had been previously digested with EcoRI andtreated with alkaline phosphatase. The resulting plasmids (pHG101-MCS,see Table 4) were used in the preparation of yeast expression vectors.

                  TABLE 4                                                         ______________________________________                                        Circumsporozoite-HBsAg Clones                                                 Insert  Number of pDC101                                                      number  Repeats   derivative   pHG101 derivative                              ______________________________________                                        MCS 29* 1         pDC101-MCS29 pHG101-MCS29                                   MCS 36* 3         pDC101-MCS36                                                MCS 33* 4         pDC101-MCS33 pHG101-MCS33                                   MCS 31* 6         pDC101-MCS31 pHG101-MCS31                                   MCS 12* 10        pDC101-MCS12 pHG101-MCS12                                   MCS 28* 7         pDC101-MCS28                                                MCS 34* 1         pDC101-MCS34                                                ______________________________________                                         *Inserts have been sequenced by M13 dideoxy method (described infra).    

4b. Construction of pC1/1-MCS by cloning the BamHI expression cassettefrom EG101-MCS into pC1/1

Plasmids pHG101-MCS29, pHG101-MCS33 and pHG101-MCS31 were digested withBamHI. The resulting fragment containing the hybrid antigen under thecontrol of the GAPDH promoter and terminator, was purified by gelelectrophoresis and ligated to BamH1 digested, alkaline phosphatasetreated pC1/1 (described previously). Ligation was carried out for 3 hrat room temperature. The reaction mixture was precipitated with ethanol,resuspended in water and used to transform E. coli HB101. PlasmidspC1/1-MCS29, pC1/1-MCS33 and pC1/1-MCS31, were thus obtained.

5. Demonstration that malaria circumsporozite epitopes and HBsAgepitopes are present in a fusion protein

To confirm that a fusion protein containing MCS and HBsAg epitopes werebeing synthesized, a Western analysis (previously described) wasperformed on yeast extracts using monoclonal antibodies against MCS orHBsAg.

To this purpose, yeast strain Saccharomyces cerevisiae PO17 (mat a, leu2-04, cir°) was transformed with pC1/1-MCS29 (or pC1/1-MCS31 orpC1/1-MCS33), pHBpreSGA347/19T or pC1/1 (the latter two are controls).Transformants were selected on leu-plates.

Single transformant colonies were inoculated into 2.5 ml of selectiveleu⁻ medium and were grown for 24 hr at 30° C. An aliguot of 0.5 ml ofthis saturated culture was inoculated into 50 ml of YEPD and grown tolow density (A₆₅₀ 1.2-2.3). Cells were harvested, and approximately 150to 300 μl of packed cells were resuspended in 100 μl of sample bufferfor protein gels (Laemmli, Nature (1970) 227 680). Samples were boiled,vortexed and insoluble material was removed by centrifugation.

An aliquot (25 μl ) of each sample was loaded onto each of two 10%polyacrylamide gels (Laemmli, supra). Both gels were electrophoresed atthe same time. After electrophoresis, proteins were blotted ontonitrocellulose filters (BA 85, 0.45 μm, Schleicher and Schuell)following the procedure of Towbin, et al. (Proc. Natl. Acad. Sci. U.S.A.(1979) 76:4350). One filter was treated with monoclonal anti-MCSantibody (2A-10) and color was developed using a second goat anti-mouseantibody conjugated with horseradish peroxidase (as previouslydescribed).

As expected, no bands reactive with anti-MCS were detected in extractsfrom pDC103 transformants. Bands of about 30 kd, 34 kd, and 35 kd weredetected in extracts from yeast transformed with pC1/1-MCS29 (onerepeat), pC1/1-MCS33 (four repeats) and pC1/1-MCS31 (six repeats). Allbands reacted with monoclonal antibody (3A11) against HBsAg when asecond identical filter was submitted to Western analysis.

These results show that a fusion protein containing both MCS and HBsAgepitopes was being synthesized in yeast cells harboring pC1/1-MCSplasmids. The fusion protein had the expected size to account for bothMCS and HBsAg fragments.

To further confirm that the hybrid antigen in yeast was present andassembled into particles, an ELISA assay for HBsAg was performed withthe extracts of transformants. Since the HBsAg monomers react verypoorly with the antibodies in the Abbott-Auzyme® immuno-assay,reactivity of the extracts in the ELISA is indicative of the presence ofassembled particles.

ELISA results from extracts of yeast transformed with pC1/1-MCS29indicated an expression level of particles of about 0.63-2.06 mg/l,while for pC1/1-MCS33, this value was about 0.22-1.22 mg/l.

The above results demonstrate that by employing hybrid DNA constructionsexpressing a particle forming polypeptide fused to a polypeptide havingan epitope of interest, particles can be produced in cells, particularlyunicellular microorganisms, where epitopic sites of both the particleforming protein and the epitope of interest are presented. In thismanner, immunogens are produced which allow for the production ofantibodies, to both the epitopes of the particle forming polypeptide andthe epitope(s) of the native polypeptide of interest fused to theparticle forming polypeptide, which polypeptide of interest is notnaturally joined to the particle forming polypeptide. In this manner,epitopes of low antigenicity can result in the formation of antibodieshaving high binding specificity and/or high titer. In addition, safe,effective vaccines can be provided where an effective immune responsecan be obtained. Furthermore, by employing a plurality of hybrid genes,particles can be obtained, having epitopes of different pathogens, sothat the same particle may serve as a carrier for vaccination againstdifferent strains of the same species, diverse pathogens, or the like.

Although the foregoing invention has been described in some detail byway of illustration and example for purposes of clarity ofunderstanding, it will be obvious that certain changes and modificationsmay be practiced within the scope of the appended claims.

What is claimed is:
 1. A method for producing antibodies to one or moreepitopes of interest which comprises:immunizing a host with a particlecomprising at least in part a hybrid polypeptide comprising a particleforming polypeptide fused to one or more polypeptides of interest, wheresaid polypeptide of interest defines an epitopic site of a pathogen ortoxin and is disposed within said particle such that said epitopic siteis immunologically reactive.
 2. A method according to claim 1, whereinsaid particle forming polypeptide is the Hepatitis B surface antigen. 3.A method according to claim 2, wherein said polypeptide of interest isfused to said particle forming polypeptides through at least a portionof the pre-surface polypeptide.
 4. DNA which has a sequence encoding ahybrid polypeptide, said hybrid polypeptide comprised of aparticle-forming polypeptide of a structural protein from a virusparticle fused to a heterologous amino acid sequence defining anepitopic site of a pathogen or toxin, wherein upon expression in acellular host, said hybrid polypeptide is capable of forming a particlesuch that said epitopic site is immunologically reactive.
 5. A methodfor producing a novel hybrid polypeptide comprising a particle formingpolypeptide fused to one or more polypeptides of interest, where saidhybrid polypeptide is capable of forming a particle in a cellular hostupon expression with presentation of at least one epitope of one of thepolypeptides of interest,said method comprising:joining a first DNAsequence coding for said particle forming polypeptide in reading frameto a DNA sequence coding for said polypeptide of interest with flankingregions having transcriptional and translational regulatory signalsrecognized by said cellular host to provide an expression DNA construct;introducing said DNA construct into said cellular host; and propagatingsaid host whereby said hybrid polypeptide is formed and aggregates intoa particle.
 6. The DNA according to claim 4 wherein said structuralprotein is from Hepatitis B surface antigen.
 7. The DNA according toclaim 6 wherein said heterologous amino acid sequence is linked to saidparticle forming polypeptide through at least about 10 contiguous aminoacids of the C-terminal portion of a pre-surface polypeptide ofHepatitis B surface antigen.
 8. The DNA according to claim 7 whereinsaid heterologous amino acid sequence is linked to said particle formingpolypeptide through about 25 amino acids of said pre-surfacepolypeptide.
 9. The DNA according to claim 4 wherein the heterologousamino acid sequence is an oligopeptide of a pathogen.
 10. The DNAaccording to claim 9 wherein said structural protein from said virusparticle is an envelope polypeptide.
 11. DNA which has a polynucleotidesequence encoding a hybrid polypeptide comprising at least a majorportion of the Hepatitis B surface antigen, wherein said antigen isfused to one or more oligopeptides comprising at least one epitope, andfurther wherein upon expression in a cellular host, the hybridpolypeptide is capable of forming a particle such that said epitope isimmunologically reactive.
 12. The DNA according to claim 11 wherein saidhost is a unicellular microorganism.
 13. The DNA according to claim 11wherein said host is a mammalian cell.
 14. The DNA according to claim 11wherein said epitope is specific for a pathogen.
 15. The DNA accordingto claim 14 wherein said epitope is present on an envelope protein. 16.DNA which has a polynucleotide sequence encoding a hybrid polypeptidecomprising Hepatitis B surface antigen linked to either an epitopicregion of the envelope D protein of herpes simplex virus or acircumsporozoite protein of Plasmodium falciparum through at least about10 contiguous amino acids of the C-terminal portion of a pre-surfacepolypeptide of Hepatitis B surface antigen.